Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414427 | 0.88 | — | — | |
| SCHEMBL21146440 | 0.87 | DPP4 (0.30) | DPP4 | |
| SCHEMBL2737401 | 0.84 | — | — | |
| SCHEMBL438971 | 0.84 | — | — | |
| SCHEMBL105168 | 0.84 | — | — | |
| SCHEMBL12718354 | 0.83 | PIK3CD (0.38) | LMNACYP2C9DPP4CHRNA7 | |
| SCHEMBL18848927 | 0.83 | PIK3CD (0.38) | LMNACYP2C9DPP4CHRNA7 | |
| SCHEMBL18842698 | 0.83 | PIK3CD (0.38) | LMNACYP2C9DPP4CHRNA7 | |
| SCHEMBL18842699 | 0.83 | PIK3CD (0.38) | LMNACYP2C9DPP4CHRNA7 | |
| SCHEMBL2603284 | 0.80 | CA12 (0.39) | DPP4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | LMNA 2483/4885CYP2C9 4012/4885SHBG 3990/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | LMNA 2483/4885CYP2C9 4012/4885SHBG 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.